Q: What is Odefsey?

Odefsey is a combination medication that contains emtricitabine , rilpivirine , and tenofovir alafenamide . It is classified as an antiretroviral drug and is primarily used in the management of human immunodeficiency virus type 1 (HIV-1) infection. The components of Odefsey work together to inhibit the replication of the virus in the body. This medication is associated with the ongoing care of individuals living with HIV-1.

Q: What is Odefsey used for?

Odefsey is used to treat HIV-1 infection.

Q: How does Odefsey work?

Mechanism of Action Odefsey contains three active ingredients: emtricitabine, rilpivirine, and tenofovir alafenamide. These drugs belong to two classes of antiretroviral medications known as nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The primary goal of these medications is to stop HIV from making copies of itself. To multiply, HIV must convert its genetic material (RNA) into DNA using an enzyme called reverse transcriptase. Odefsey interferes with this process in two ways: Blocking the building process: Emtricitabine and tenofovir alafenamide act as faulty building blocks. When the virus tries to use them to build its DNA, the process is interrupted, and the DNA chain cannot be completed. Disabling the enzyme: Rilpivirine binds directly to the reverse transcriptase enzyme, physically preventing it from working. By interfering with this replication process, Odefsey reduces the viral load, which is the amount of HIV in the blood. This allows the immune system, specifically CD4 cells, to recover and better protect the body against infections. While Odefsey helps manage HIV, it is not a cure for the virus.

Q: What are the active ingredients in Odefsey?

The active ingredients in Odefsey are rilpivirine , tenofovir alafenamide , and emtricitabine .

Q: What are the side effects of Odefsey?

Common side effects of Odefsey may include: Nausea Headache Fatigue and others. Always consult with a healthcare professional about potential side effects.

Q: What is the dosage of Odefsey and how do I take it?

How to Take Odefsey Odefsey is a complete treatment for HIV-1 infection. It is taken as a single tablet once every day. It is important to take the medication exactly as prescribed by your healthcare provider. This medication must be taken with a meal. Taking it with food helps your body absorb the medicine correctly. A protein drink or nutritional supplement is not considered a substitute for a meal. Try to take your dose at the same time each day to maintain a steady level of the medicine in your system. Do not stop taking this medication or change your dose without consulting your healthcare provider, as this can lead to the virus becoming harder to treat. Missed Dose If you miss a dose, take it as soon as you remember, provided it is taken with a meal. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed one.

Q: Is Odefsey safe during pregnancy and breastfeeding?

Pregnancy Data regarding the use of Odefsey in pregnant individuals is limited. While animal studies on the individual components of the medication have generally not shown an increased risk of birth defects, there is not enough human data to establish a drug-associated risk. It has been observed that blood levels of rilpivirine, one of the components in Odefsey, may be lower during the second and third trimesters of pregnancy. Consequently, healthcare providers may monitor viral loads more closely to ensure the medication remains effective during this time. There is an Antiretroviral Pregnancy Registry that monitors outcomes in individuals who take HIV medications while pregnant. Healthcare providers are encouraged to register patients to help collect more information about the safety of Odefsey during pregnancy. Breastfeeding The Centers for Disease Control and Prevention (CDC) recommends that individuals with HIV-1 in the United States do not breastfeed their infants. This is primarily to avoid the risk of transmitting the virus to the baby after birth. Additionally, there is a risk that the infant could develop resistance to HIV medications if they are exposed to the drug through breast milk. One of the active ingredients in Odefsey, emtricitabine, has been shown to pass into human breast milk. It is currently unknown if the other components, rilpivirine or tenofovir alafenamide, are present in human milk. Because of the potential for HIV transmission and the risk of adverse reactions in the nursing infant, breastfeeding is not recommended while using this medication.

Q: What is the FDA approval status of Odefsey?

FDA Approval Odefsey was approved by the U.S. Food and Drug Administration (FDA) on March 1, 2016. It is a fixed-dose combination tablet containing emtricitabine, rilpivirine, and tenofovir alafenamide. Approved Indications Odefsey is indicated as a complete treatment for HIV-1 infection in adults and pediatric patients weighing at least 35 kg who meet the following criteria: They have no history of antiretroviral treatment and have HIV-1 RNA levels less than or equal to 100,000 copies/mL. They are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least six months, have no history of treatment failure, and have no known resistance to the components of Odefsey. Boxed Warning Odefsey includes a boxed warning regarding the risk of severe acute exacerbations of hepatitis B (HBV). Patients co-infected with HIV-1 and HBV may experience a severe worsening of hepatitis B if they stop taking Odefsey. Healthcare providers typically test patients for HBV infection before starting treatment. If Odefsey is discontinued in co-infected patients, liver function should be monitored closely for several months.

Question 1

What is Odefsey?

Accepted Answer

Odefsey is a combination medication that contains emtricitabine, rilpivirine, and tenofovir alafenamide. It is classified as an antiretroviral drug and is primarily used in the management of human immunodeficiency virus type 1 (HIV-1) infection. The components of Odefsey work together to inhibit the replication of the virus in the body. This medication is associated with the ongoing care of individuals living with HIV-1.

Question 2

What is Odefsey used for?

Accepted Answer

Odefsey is used to treat HIV-1 infection.

Question 3

How does Odefsey work?

Accepted Answer

Mechanism of Action

Odefsey contains three active ingredients: emtricitabine, rilpivirine, and tenofovir alafenamide. These drugs belong to two classes of antiretroviral medications known as nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).

The primary goal of these medications is to stop HIV from making copies of itself. To multiply, HIV must convert its genetic material (RNA) into DNA using an enzyme called reverse transcriptase. Odefsey interferes with this process in two ways:

Blocking the building process: Emtricitabine and tenofovir alafenamide act as faulty building blocks. When the virus tries to use them to build its DNA, the process is interrupted, and the DNA chain cannot be completed.
Disabling the enzyme: Rilpivirine binds directly to the reverse transcriptase enzyme, physically preventing it from working.

By interfering with this replication process, Odefsey reduces the viral load, which is the amount of HIV in the blood. This allows the immune system, specifically CD4 cells, to recover and better protect the body against infections. While Odefsey helps manage HIV, it is not a cure for the virus.

Question 4

What are the active ingredients in Odefsey?

Accepted Answer

The active ingredients in Odefsey are rilpivirine, tenofovir alafenamide, and emtricitabine.

Question 5

What are the side effects of Odefsey?

Accepted Answer

Common side effects of Odefsey may include:

Nausea
Headache
Fatigue
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Odefsey?

Accepted Answer

Odefsey belongs to the antiretroviral combination drug class.

Question 7

What is the dosage of Odefsey and how do I take it?

Accepted Answer

How to Take Odefsey

Odefsey is a complete treatment for HIV-1 infection. It is taken as a single tablet once every day. It is important to take the medication exactly as prescribed by your healthcare provider.

This medication must be taken with a meal. Taking it with food helps your body absorb the medicine correctly. A protein drink or nutritional supplement is not considered a substitute for a meal.

Try to take your dose at the same time each day to maintain a steady level of the medicine in your system. Do not stop taking this medication or change your dose without consulting your healthcare provider, as this can lead to the virus becoming harder to treat.

Missed Dose

If you miss a dose, take it as soon as you remember, provided it is taken with a meal. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed one.

Question 8

Is Odefsey safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data regarding the use of Odefsey in pregnant individuals is limited. While animal studies on the individual components of the medication have generally not shown an increased risk of birth defects, there is not enough human data to establish a drug-associated risk. It has been observed that blood levels of rilpivirine, one of the components in Odefsey, may be lower during the second and third trimesters of pregnancy. Consequently, healthcare providers may monitor viral loads more closely to ensure the medication remains effective during this time.

There is an Antiretroviral Pregnancy Registry that monitors outcomes in individuals who take HIV medications while pregnant. Healthcare providers are encouraged to register patients to help collect more information about the safety of Odefsey during pregnancy.

Breastfeeding

The Centers for Disease Control and Prevention (CDC) recommends that individuals with HIV-1 in the United States do not breastfeed their infants. This is primarily to avoid the risk of transmitting the virus to the baby after birth. Additionally, there is a risk that the infant could develop resistance to HIV medications if they are exposed to the drug through breast milk.

One of the active ingredients in Odefsey, emtricitabine, has been shown to pass into human breast milk. It is currently unknown if the other components, rilpivirine or tenofovir alafenamide, are present in human milk. Because of the potential for HIV transmission and the risk of adverse reactions in the nursing infant, breastfeeding is not recommended while using this medication.

Question 9

What forms and strengths does Odefsey come in?

Accepted Answer

Odefsey is supplied as a film-coated tablet intended for oral administration. This medication is a fixed-dose combination product, meaning multiple active ingredients are contained within a single tablet. The tablets are typically debossed with specific markings on one side to assist with identification.

Question 10

What is the FDA approval status of Odefsey?

Accepted Answer

FDA Approval

Odefsey was approved by the U.S. Food and Drug Administration (FDA) on March 1, 2016. It is a fixed-dose combination tablet containing emtricitabine, rilpivirine, and tenofovir alafenamide.

Approved Indications

Odefsey is indicated as a complete treatment for HIV-1 infection in adults and pediatric patients weighing at least 35 kg who meet the following criteria:

They have no history of antiretroviral treatment and have HIV-1 RNA levels less than or equal to 100,000 copies/mL.
They are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least six months, have no history of treatment failure, and have no known resistance to the components of Odefsey.

Boxed Warning

Odefsey includes a boxed warning regarding the risk of severe acute exacerbations of hepatitis B (HBV). Patients co-infected with HIV-1 and HBV may experience a severe worsening of hepatitis B if they stop taking Odefsey. Healthcare providers typically test patients for HBV infection before starting treatment. If Odefsey is discontinued in co-infected patients, liver function should be monitored closely for several months.

Question 11

What should I know about Odefsey and cost?

Accepted Answer

Insurance and Pharmacy Factors

The out-of-pocket cost for Odefsey is primarily determined by your health insurance plan. Most plans include Odefsey on their formulary, but the specific tier level will dictate the copayment or coinsurance amount. For those without insurance, the retail price may vary between different pharmacies and geographic locations.

Financial Assistance Programs

There are several options that may help reduce the cost of Odefsey:

Copay Cards: The manufacturer may offer savings cards for patients with commercial insurance to lower monthly out-of-pocket expenses.
Patient Assistance: Programs are often available for individuals who lack insurance or have limited financial resources, providing the medication at a reduced cost or for free to those who qualify.

Generic Availability

Odefsey is a brand-name medication. At this time, there are no generic versions of this specific combination tablet available in the United States. Generic medications are typically less expensive than brand-name versions.

Odefsey

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Odefsey

Hospitals.net Disclosure